Science Current Events | Science News |

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012

CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research

Related Bevacizumab Current Events and Bevacizumab News Articles

Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS
Results of EORTC trial 26101 presented today at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.

Ranibizumab found effective against diabetic retinopathy
In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab -- a drug most commonly used to treat retinal swelling in people with diabetes -- is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease.

Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast cancer
A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to another kind of treatment.

Fears of potentially blinding complication from Avastin eye injections overblown, says Penn study
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Thin colorectal cancer patients have shorter survival than obese patients
Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.

Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit.

Development of new blood vessels not essential to growth of lymph node metastases
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed.

Study suggests new way of preventing diabetes-associated blindness
Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

TGen-UCSF study in Neuro-Oncology provides comprehensive look at brain cancer treatments
Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press journal Neuro-Oncology.

Allow NHS doctors to prescribe cheap, safe and effective sight loss drug, says The BMJ
NHS doctors should be allowed to prescribe a cheap, safe and effective drug for the degenerative eye disease, wet age related macular degeneration (AMD) - a leading cause of blindness among older patients, says an investigation by The BMJ today.
More Bevacizumab Current Events and Bevacizumab News Articles

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

“Although, your health condition may impact your everyday life, do not let it define who you are.”

AVASTIN (Bevacizumab) injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. AVASTIN (Bevacizumab) is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow. AVASTIN (Bevacizumab) injection is also used in combination with other medicines (eg,...

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

All About Bevacizumab

All About Bevacizumab
by Aneta Zygulska (Author), Krzysztof Krzemieniecki (Author)

Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. No available published data on the influence of bevacizumab on macrocytosis has been so far. This paper attempts to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Moreover, treatment of solid tumors and non-cancerous diseases is discussed in the second part of this paper.

Introducción a la genética humana, 3ª ed. (Spanish Edition)

Introducción a la genética humana, 3ª ed. (Spanish Edition)
by Editorial El Manual Moderno

Los autores de la primera y segunda edición de esta obra, fuimos los Drs. Salvador Armendares y un servidor. Ya han pasado 18 años desde que apareció la primera y 11 de la segunda, por lo que parecía necesario actualizarla una vez más, en vista de los avances considerables del conocimiento en esta área. Para ello y dado el fallecimiento de Salvador en enero de 2010, me pareció necesario invitar a colaborar a dos distinguidos colegas. La Dra. Patricia Grether González, ex alumna mía, conocedora de los aspectos clínicos de la genética y el Dr. Alejandro Zentella Dehesa, investigador básico en el campo de la biología molecular a quien conozco hace relativamente pocos años pero quien parece tener la capacidad de expresar temas complejos de una manera sencilla, característica...

Eficacia comparada: XELOX vs XELOX+Bevacizumab en cancer colorrectal metastasico: Trabajo Diploma Oncologia Farmaceutica. Edicion 2010. Universidad de Valencia. (Spanish Edition)

Eficacia comparada: XELOX vs XELOX+Bevacizumab en cancer colorrectal metastasico: Trabajo Diploma Oncologia Farmaceutica. Edicion 2010. Universidad de Valencia. (Spanish Edition)
by Marta Mª Valera Rubio (Author)

Estudio comparativo de eficacia entre el esquema XELOX y el esquema XELOX+Bevacizumab en cáncer colorrectal metastásico en una población de un hospital de tercer nivel.

Ending Medical Reversal: Improving Outcomes, Saving Lives

Ending Medical Reversal: Improving Outcomes, Saving Lives
by Vinayak K. Prasad (Author), Adam S. Cifu (Author)

We expect medicine to progress in an orderly fashion, with good medical practices being replaced by better ones. But some tests and therapies are discontinued because they are found to be worse, or at least no better, than what they replaced. Medications like Vioxx and procedures such as vertebroplasty for back pain caused by compression fractures are among the medical "advances" that turned out to be dangerous or useless. What Dr. Vinayak K. Prasad and Dr. Adam S. Cifu call medical reversal happens when doctors start using a medication, procedure, or diagnostic tool without a robust evidence base―and then stop using it when it is found not to help, or even to harm, patients.Drs. Prasad and Cifu narrate fascinating stories from every corner of medicine to explore why medical reversals...

Hemophilia and Hemostasis: A Case-Based Approach to Management

Hemophilia and Hemostasis: A Case-Based Approach to Management
by Alice D. Ma (Editor), Harold R. Roberts (Editor), Miguel A. Escobar (Editor)

There is a general need amongst healthcare professionals for practical advice on the management of patients with bleeding disorders. This book is an essential resource for all those working in the fields of coagulation, hemostasis and thrombosis. It covers the major cases one might encounter in diagnosing, managing and treating hemophilia and hemostasis. It provides a practical and informative guide to the broad range of topics concerning both bleeding and clotting disorders.  The book is divided into major chapter sections depending on the type of bleeding disorder it fits into. Each chapter includes a brief overview of the disorder covering: history of the disorder; molecular basis of the disorder; class presentation; genetics; current laboratory tests and monitoring. Cases associated...

  Cotargeting VEGF and Neuropilins with Bevacizumab and Secreted Wnt Inhibitors in Prostate Cancer
by Xiaolin Zi (Author)

All About Bevacizumab [PAPERBACK] [2013] [By Aneta Zygulska]

All About Bevacizumab [PAPERBACK] [2013] [By Aneta Zygulska]
by Aneta Zygulska (Author)

Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer

Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer
by Thomas Seyfried (Author)

The book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due...

© 2015